Ahmed Idbaih
Prof Ahmed Idbaih is an expert in Neurology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Ahmed Idbaih in the top 1% of experts worldwide for Glioma, Brain Neoplasms and Nervous System Neoplasms. Ahmed Idbaih has authored 498 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 6 of them ongoing. SLR score: 1,965 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Oncology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2004 - 2026
Number : 498
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Reference frame for Adult Brainstem gliomas. PMID 42860045 — glioma, neoplasms, biopsy, brain stem, diagnosis, therapeutics | Oncologist | 2026 | 0 |
| MEK inhibition achieves robust and durable responses in Erdheim-Chester disease. PMID 42840804 — safety, erdheim-chester disease, probability, therapeutics, retention, psychology | Hemasphere | 2026 | 0 |
| CBL Variants in Suspected Histiocytic Neoplasms: A Retrospective Study of 11 Cases. PMID 42758873 — hematology, retrospective studies, neoplasms | Hematol Oncol | 2026 | 0 |
| Targeted proteomics reveal histiocytosis-associated neurodegeneration signatures. PMID 42707979 — biomarkers, histiocytosis, proteomics, plasma | Hemasphere | 2026 | 0 |
| Molecular profiling and access to treatment for rare cancers in Europe. PMID 42642364 — biological science disciplines, neoplasms, therapeutics | Nat Commun | 2026 | 0 |
Clinical Studies 17
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase III Study of TLX101 Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma 2025-521785-10-00 — injections, safety, lomustine, solutions, glioblastoma, therapeutics | Phase 3 | Recruiting | 2026 |
| New adjuvant vaccine in glioblastoma a Phase 1 2a study (NAVIG 1) 2024-514567-26-00 — vaccines, glioblastoma | Phase 1/Phase 2 | Recruiting | 2024 |
| Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas NCT07472387 — blood, blood specimen collection, circadian rhythm, androgens, neoplasms, chemoradiotherapy, glioblastoma, sex, specimen handling, therapeutics, hydrocortisone, tissues, male, men | N/A | Not yet recruiting | 2026 |
| New Adjuvant Vaccine in Glioblastoma a Phase 1 2a Study NCT06622434 — cells, immunization, immunomodulation, safety, vaccines, antibodies, temozolomide, melanins, neoplasms, telomerase, chemoradiotherapy, glioblastoma, therapeutics, cancer vaccines | Phase 1/Phase 2 | Recruiting | 2024 |
| Sonocloud 9 in Association With Carboplatin Versus Standard of Care Chemotherapies (CCNU or TMZ) in Recurrent GBM NCT05902169 — blood-brain barrier, glomerular filtration rate, blood, temozolomide, pharmaceutical preparations, acoustics, brain, lomustine, drug therapy, glioblastoma, therapeutics, tissues, carboplatin, blood vessels, chemotherapy | Phase 3 | Recruiting | 2024 |
LeadR Networks
Main global connection map